![]() 988,590,948 visitors served. |
|
![]() Dictionary/ thesaurus | ![]() Medical dictionary | ![]() Legal dictionary | ![]() Financial dictionary | ![]() Acronyms | ![]() Idioms | ![]() Encyclopedia | ![]() Wikipedia encyclopedia | ? |
ligand |
Also found in: Dictionary/thesaurus, Encyclopedia, Wikipedia, Hutchinson | 0.04 sec. |
|
ligand /li·gand/ (li´gand) (lig´and) an organic molecule that donates the necessary electrons to form coordinate covalent bonds with metallic ions. Also, an ion or molecule that reacts to form a complex with another molecule.
ligand (līg n 1. a molecule, ion, or group bound to the central atom of a chemical compound, such as the oxygen molecule in hemoglobin, which is bound to the central iron atom. 2. an organic molecule attached to a specific site on a surface or to a tracer element. ligand an organic molecule that donates the necessary electrons to form coordinate covalent bonds with metallic ions. Also, an ion or part of a molecule that specifically binds to form a complex with another molecule. |
|
? Mentioned in | ? References in periodicals archive | |
|---|---|---|
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), San Diego, has submitted a regulatory application to market its anti-cancer medicine ONZAR(TM) (denileukin diftitox) in the European Union for the treatment of cutaneous T-cell lymphoma (CTCL) patients. SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that its stockholders approved all the matters proposed in the Company's recent proxy statement, including the approval of the sale of AVINZA and related assets to King Pharmaceuticals, Inc. SAN DIEGO -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that a special meeting of Ligand's stockholders will be held on February 12, 2007 to vote on approval of the sale of AVINZA and related assets to King Pharmaceuticals, Inc. |
| Free Tools: |
For surfers:
Browser extension |
Word of the Day |
Help
For webmasters: Free content NEW! | Linking | Lookup box | Double-click lookup | Partner with us |
|
|---|